Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Barth Green

Neurological Surgery Miami, FL Medical Doctor

NPI 1730106204 CMS profile 304760

1475 Nw 12Th Avenue, Miami, FL 33136

Open in the dashboard

General payments

$499

9 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Barth Green of Miami, FL is reported in the CMS Open Payments database as having received $499 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $192 2
2021 General $216 3
2020 General $13 1
2019 General $77 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barth Green
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Barth Green were reported at $0. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Barth Green Neurological Surgery median Middle half National median
2019 $77 $582 $138–$3,006 $163
2020 $13 $294 $76–$2,174 $114
2021 $216 $387 $105–$2,432 $132
2022 $0 $542 $139–$2,989 $149
2023 $192 $534 $145–$2,697 $160
2024 $0 $574 $155–$3,046 $164
2025 $0 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. NuVasive, Inc. $408 5 payments
  2. AxoGen $47 1 payment
  3. Pfizer Inc. $44 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $499 9 payments
Products named General payments · program years 2019–2023
  1. XLIF $302 2 payments
  2. RELINE $173 1 payment
  3. VuePoint $173 1 payment
  4. AxoGuard Nerve Connector $47 1 payment
  5. AXOGUARD NERVE PROTECTOR $47 1 payment
  6. LYRICA $30 2 payments
  7. ACP $20 1 payment
  8. COLOGUARD $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

309

Median for Neurosurgery: 83

Drug cost

$6,056

Median for Neurosurgery: $872

Branded share of claims

11%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 119 $1,927
Duloxetine Hcl Generic 73 $1,602
Celecoxib Generic 28 $1,343
Pregabalin Generic 27 $417
Baclofen Generic 15 $334
Vitamin D2 Ergocalciferol (Vitamin D2) Brand 34 $315
Methylprednisolone Generic 13 $118

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$19,663

Medicare's payments for the services billed

Medicare patients

123

Average age 73

Services billed

208

67 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 41%
Osteoporosis 31%
Diabetes 25%
Depression 25%
Chronic kidney disease 22%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record